肌萎缩侧索硬化患者4种血清NfL检测法及pTau181、GFAP的性能比较
在法国蒙彼利埃ALS中心的139例ALS患者和70例非ALS患者中,头对头比较4种血清NfL检测法及GFAP、pTau181的诊断与预后性能;NfL各法高度相关,诊断ALS的AUC为0.889至0.912,预后HR为4.4至5.4,而GFAP和pTau181诊断性能差。
要点
- 4种血清NfL免疫检测法高度相关(R²=0.939至0.963),诊断ALS的AUC为0.889至0.912。
- 血清NfL用于ALS生存分析的HR为4.4至5.4;低于预后截断值者50周生存概率40%至50%。
- 血清GFAP和pTau181诊断ALS的AUC分别为0.546和0.565,诊断性能差。
核心结论
- 4种免疫检测法在ALS患者血清NfL定量中表现一致,NfL诊断和预后准确性高,适合个体评估,而GFAP或pTau181不适合。
- 作者提出血清NfL的诊断和预后截断值,为更广泛实施提供基础,尤其是临床认证的Lumipulse和Elecsys平台正成为标准实践。
研究设计与样本
- 来自蒙彼利埃ALS中心的队列,头对头比较4种技术检测血清NfL(Simoa、Ella、Lumipulse、Elecsys)以及Elecsys检测血清GFAP和pTau181。
- 队列纳入139例ALS患者和70例非ALS患者,平均年龄66.1±11.4岁,女性占47.4%。
- ALS患者平均随访42±26.3个月,非ALS患者平均随访141.6±106.3个月,死亡率分别为85.5%和7.7%。
主要发现
- 所有血清NfL定量方法间高度相关,R²=0.939至0.963。
- 诊断ALS的AUC:NfL Simoa为0.889(0.827-0.932),Ella为0.906(0.847-0.944),Lumipulse为0.912(0.853-0.948),Elecsys为0.910(0.851-0.946)。
- 血清pTau181和GFAP诊断性能差,AUC分别为0.565(0.472-0.649)和0.546(0.461-0.636)。
- Kaplan-Meier生存分析显示血NfL的风险比为4.4至5.4;低于预后截断值的ALS患者50周生存概率为40%至50%,高于截断值者生存率降至接近零。
- NfL和GFAP水平与年龄和体重指数相关,被视为混杂因素;pTau181水平在ALS患者中随起病部位显著变化。
关键数值与推荐
- 血清NfL诊断ALS的AUC为0.889至0.912,各检测法具体值见findings。
- 血清NfL用于生存分析的风险比为4.4至5.4。
- 血清GFAP和pTau181诊断ALS的AUC分别为0.546和0.565。
- 证据分类:本研究提供II类证据,表明血清NfL水平有助于识别超过80%的ALS患者并预测生存,优于pTau181和GFAP水平。
临床怎么用
- 作者提出血清NfL的诊断和预后截断值,为更广泛实施提供基础,尤其是临床认证的Lumipulse和Elecsys平台正成为标准实践。
- 作者认为NfL适合个体评估,而GFAP或pTau181不适合。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Selecting the most appropriate blood tests is crucial for the management of patients with amyotrophic lateral sclerosis (ALS). This study evaluates the diagnostic and prognostic performance of neurofilament light chain (NfL), glial fibrillary acidic protein (GFAP), and phosphorylated tau 181 (pTau181) biomarkers in ALS to establish their clinical relevance and cutoff values. METHODS: In a cohort of patients from the ALS center in Montpellier, we conducted a head-to-head comparison of 4 different technologies and 3 distinct serum analytes: NfL was tested using the ultrasensitive Simoa and the microfluidic Ella platforms, along with 2 assays recently set up on clinical-grade platforms: Lumipulse and Elecsys. We also used Elecsys to assess serum GFAP and pTau181. RESULTS: Our cohort included 139 patients with ALS and 70 non-ALS patients, with a mean age of 66.1 ± 11.4 years and 47.4% of women. The mean follow-up was 42 ± 26.3 months for patients with ALS and 141.6 ± 106.3 months for non-ALS patients, with a mortality rate of 85.5% vs 7.7%. There was a high correlation between all methods tested for serum NfL quantification (R2 = 0.939 to 0.963). The area under the curve (AUC) for ALS diagnosis was 0.889 (0.827-0.932) for NfL Simoa, 0.906 (0.847-0.944) for Ella, 0.912 (0.853-0.948) for Lumipulse, and 0.910 (0.851-0.946) for Elecsys. Serum pTau181 and GFAP showed poor diagnostic performance with AUCs of 0.565 (0.472-0.649) and 0.546 (0.461-0.636), respectively. Kaplan-Meier survival analysis revealed significant hazard ratios (4.4-5.4) for blood NfL. Patients with ALS had a 40%-50% chance of surviving 50 weeks below the prognostic cutoff values while survival rates dropped to near zero above. NfL and GFAP levels were associated with age and body mass index, considered confounding factors. pTau181 levels varied significantly in patients with ALS depending on the site of onset. DISCUSSION: This study demonstrates the consistent performance of 4 immunoassays for serum NfL quantification in ALS. NfL showed high diagnostic and prognostic accuracy, making it suitable for individual assessment, unlike GFAP or pTau181. We propose diagnostic and prognostic cutoff values for serum NfL, providing a basis for wider implementation, especially with the clinically accredited Lumipulse and Elecsys platforms, which are becoming standard practice. CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that serum NfL levels are useful in identifying over 80% of patients with ALS and predicting survival in patients with ALS compared with pTau181 and GFAP levels.
引用
- Mondesert E, Delaby C, De La Cruz E, et al. Comparative Performances of 4 Serum NfL Assays, pTau181, and GFAP in Patients With Amyotrophic Lateral Sclerosis. Neurology. 2025. PMID: 40009787. doi:10.1212/WNL.0000000000213400
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。